Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
dc.contributor.author | Rule, S | |
dc.contributor.author | Cook, G | |
dc.contributor.author | Russell, NH | |
dc.contributor.author | Hunter, A | |
dc.contributor.author | Robinson, S | |
dc.contributor.author | Morley, N | |
dc.contributor.author | Sureda, A | |
dc.contributor.author | Patrick, P | |
dc.contributor.author | Clifton-Hadley, L | |
dc.contributor.author | Adedayo, T | |
dc.contributor.author | Kirkwood, A | |
dc.contributor.author | Peggs, KS | |
dc.date.accessioned | 2019-02-12T13:53:39Z | |
dc.date.issued | 2018-12-17 | |
dc.identifier.issn | 0007-1048 | |
dc.identifier.issn | 1365-2141 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/13295 | |
dc.description.abstract |
Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma that remains incurable for the majority of patients. Allogeneic stem cell transplantation (alloSCT) produces long-term disease-free remissions for around 30-40% patients, however it is reserved for the treatment of relapsed disease. This study examined the use of front line transplantation for young patients in an attempt to improve outcomes. Twenty-five patients received an alloSCT using BEAM [BCNU (carmustine), etoposide, cytarabine, melphalan)-Campath conditioning following permissive induction therapy from both related and unrelated donors. This was a multi-centre prospective trial. Twenty-four of 25 patients engrafted with no non-relapse mortality events by day 100. With a median follow-up of 60·5 months, there have been six deaths (3 from MCL). The progression-free survival (PFS) and overall survival were 68% and 80% at 2 years and 56% and 76% at 5 years. PFS was very similar for both sibling and unrelated transplants and there was no difference in PFS between patients with respect to remission status prior to transplantation. Nine (38%) patients experienced acute graft-versus-host disease (GVHD) and 14 (58%) experienced chronic GVHD, of which 8 were extensive. Front line alloSCT is feasible but should only be considered for patients at high risk of early progression following conventional therapy. | |
dc.format.extent | 999-1005 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Wiley | |
dc.subject | clinical trials | |
dc.subject | non-Hodgkin lymphoma | |
dc.subject | stem cell transplantation | |
dc.title | Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. | |
dc.type | journal-article | |
dc.type | Article | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/30560573 | |
plymouth.issue | 6 | |
plymouth.volume | 184 | |
plymouth.publication-status | Published | |
plymouth.journal | British Journal of Haematology | |
dc.identifier.doi | 10.1111/bjh.15723 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2018-10-15 | |
dc.rights.embargodate | 2019-12-17 | |
dc.identifier.eissn | 1365-2141 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.funder | Cancer Research UK | |
rioxxterms.identifier.project | CRUK/08/020: Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma | |
rioxxterms.versionofrecord | 10.1111/bjh.15723 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-12-17 | |
rioxxterms.type | Journal Article/Review | |
plymouth.funder | CRUK/08/020: Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma::Cancer Research UK |